Lysosomal Storage Diseases

Lysosomal Storage Diseases are a group of rare genetic disorders. They happen when the body can't break down certain substances properly. This causes those substances to build up inside special parts of cells called lysosomes. This buildup can damage different parts of the body.

Condition

What people with Lysosomal Storage Diseases report

Every report comes from a Lived member, sent anonymously.

Have you tried Enzyme Replacement Therapy for Lysosomal Storage Diseases?

NameHow it went

About Lysosomal Storage Diseases

What It Is

Lysosomal storage diseases are a group of more than 70 inherited disorders in which cells cannot properly break down or clear certain fats, sugars or proteins. Normally, small compartments inside cells called lysosomes act as recycling centers, using enzymes to take these materials apart. When one enzyme or transport protein is missing or not working, the material it handles builds up (is "stored") and gradually damages cells and the organs they make up. Each disorder is rare, but together they affect roughly 1 in 5,000 babies. Familiar names in the group include Gaucher disease, Fabry disease, Pompe disease, Tay-Sachs disease, Niemann-Pick disease, Krabbe disease and the mucopolysaccharidoses (MPS), such as Hunter syndrome, in which complex sugar chains build up and often affect the bones, joints and facial features. Which organs are affected depends on what is being stored. Many of these disorders affect the brain and nerves, while others mainly affect the liver and spleen, bones, heart, muscles or kidneys. Most begin in infancy or childhood, but some forms first appear in teenagers or adults, and severity can differ widely even within one disorder.

Causes & Risk Factors

These disorders are caused by changes in a single gene that a person inherits. They are not caused by anything a person or parent did. Most follow an autosomal recessive pattern: each parent carries one altered copy of the gene but is usually healthy, and when both parents are carriers, each child has a 25% chance of having the disorder and a 50% chance of being a carrier. A few are X-linked, meaning the gene sits on the X chromosome. Fabry disease and MPS II (Hunter syndrome) are examples. Males, who have one X chromosome, are typically more affected. In Fabry disease, women and girls with one altered copy can also have symptoms, often milder and more variable. Some disorders are more common in particular communities; Gaucher disease and Niemann-Pick disease type A, for example, occur more often in people of Ashkenazi Jewish ancestry. A family history of one of these disorders is the most useful clue to risk.

How It's Diagnosed

Because the early signs, such as delayed development, an enlarged liver or spleen, bone problems or poor muscle tone, overlap with many other conditions, these disorders can be hard to recognize at first. Diagnosis usually starts with a specialist in genetic or metabolic conditions reviewing symptoms, an examination and family history. The key tests look directly at the suspected defect. An enzyme activity test, often done on a blood sample, shows whether a specific enzyme is working at a normal level. Urine tests can detect some stored materials. Genetic testing identifies the gene change, confirms the exact disorder and allows relatives to be tested. Imaging, eye exams, heart and hearing tests then show which organs are involved. Some disorders, such as Pompe disease and MPS I, are included in newborn screening in many US states, though which disorders are screened varies by state. An abnormal screen is not a diagnosis by itself; it leads to confirmatory enzyme and genetic testing.

Treatment Options

Treatment depends entirely on the specific disorder. Current therapies do not cure these conditions, but for a growing number of them they can slow progression, reduce organ damage and improve survival and quality of life. For many others, care is supportive: managing nutrition and feeding, breathing, seizures, pain, mobility and infections. Enzyme replacement therapy supplies a manufactured version of the missing enzyme, usually by intravenous infusion, usually every week or every two weeks for life. It is approved for several disorders, including Gaucher, Fabry and Pompe diseases and several MPS types, and can shrink an enlarged liver and spleen, help stabilize heart and kidney function and reduce some pain. Its major limitation is that it does not cross into the brain well, so it does little for brain and spinal cord symptoms. Infusion reactions, including allergic reactions, can occur, and some people develop antibodies that make the enzyme less effective. Other options apply to particular disorders. Substrate reduction therapy is an oral medicine that lowers how much of the stored material the body makes; eliglustat (Cerdelga) is one used for Gaucher disease type 1. Chaperone therapy helps a misfolded enzyme work, but only for people with specific gene variants; migalastat (Galafold), a capsule for adults with Fabry disease, is one example. A stem cell transplant from a healthy donor can supply working enzyme for a limited number of disorders, typically when done early. Gene therapy is beginning to reach patients: atidarsagene autotemcel (Lenmeldy) was approved in 2024 for metachromatic leukodystrophy, a disorder in this group that damages the brain and nerves. It is for children treated before symptoms appear or, in one later-starting form, very soon after they begin, and it uses a child's own blood stem cells with a working gene added, after high-dose chemotherapy. Because these treatments are specialized and costly, care is usually led by a metabolic or genetics center.

What to Expect

The outlook varies more across this group than almost any other diagnosis. Severe infantile forms of disorders such as Tay-Sachs or Krabbe disease progress quickly, and infantile Krabbe disease is usually fatal before age 2. Later-onset forms of the same disorders are generally milder and progress more slowly, and conditions such as Gaucher disease type 1 or Fabry disease are often managed with treatment over many years. Knowing the exact disorder and form is the most important step in understanding what lies ahead. Most people need long-term care from a team that may include metabolic, neurology, heart, kidney, bone and therapy specialists. Regular tests track organ function and whether treatment is working. Enzyme replacement means a recurring infusion schedule that shapes daily routines. Families caring for a child with a progressive neurological form often need support with feeding, equipment, school and respite. Genetic counseling helps relatives understand their own carrier risk and options for future pregnancies, and patient organizations for specific disorders can connect families with others who share the same diagnosis.

When to Seek Help

Ask for an evaluation when a child has unexplained developmental delays, an enlarged belly from liver or spleen growth, recurring bone pain or skeletal changes, or poor muscle tone, especially with a family history of a lysosomal storage disease. Adults with unexplained burning pain in the hands and feet, early kidney or heart problems, or a relative with Fabry or Gaucher disease should ask whether testing makes sense. Follow up promptly on an abnormal newborn screening result, since some infant forms respond best when treatment starts early. For someone already diagnosed, contact the care team promptly about loss of skills they had already learned, a first or new type of seizure, or swallowing or breathing that is gradually becoming harder. Call 911 for severe trouble breathing, such as struggling for each breath or bluish lips, or for a seizure that lasts longer than 5 minutes.

Questions to Ask Your Doctor

  1. 1.Which specific disorder and form is this, and what does that mean for how it is likely to progress?
  2. 2.Is there an approved treatment for this disorder, and what can it realistically change, especially for any brain or nerve symptoms?
  3. 3.Would a stem cell transplant, gene therapy or a clinical trial be worth considering, and how does timing affect that choice?
  4. 4.Which specialists should be part of the care team, and which tests will we use to track changes over time?
  5. 5.Should other family members have carrier or diagnostic testing, and can we meet with a genetic counselor?

Last reviewed • Oct 2026

Educational content, not medical advice.